You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

Article metrics

Article menu

Download PDFPDF

Poster Presentation
Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer
Free

 

Online download statistics by month:

Online download statistics by month: December 2019 to August 2024

AbstractFullPdf
Dec 2019010
Jan 2020010
Feb 2020010
Apr 2020011
May 2020020
Jun 20200100
Jul 2020030
Aug 2020011
Sep 2020074
Oct 2020051
Nov 2020020
Dec 2020011
Jan 2021031
Feb 2021001
Mar 2021020
Apr 2021061
May 2021040
Jun 2021021
Jul 2021060
Aug 2021050
Sep 2021030
Oct 20210113
Nov 20210116
Dec 20210110
Jan 20220123
Feb 2022081
Mar 2022032
Apr 2022040
May 2022051
Jun 20220122
Jul 20220111
Aug 20220134
Sep 20220151
Oct 2022091
Nov 20220201
Dec 20220162
Jan 20230122
Feb 20230113
Mar 2023050
Apr 2023040
May 2023041
Jun 2023031
Jul 2023021
Aug 2023020
Sep 2023050
Oct 2023031
Nov 2023062
Dec 20230120
Jan 2024080
Feb 20240122
Mar 2024030
Apr 2024040
May 2024060
Jun 2024040
Jul 2024062
Aug 2024050
Total034455